Extrait

Tolerability (number of cycles of consolidation therapy; toxicity) of intensified consolidation therapy in elderly AML patients Adverse event profile

Critère d'inclusion

• Acute myeloid leukemia (AML), de novo, FAB classification other than M3 or WHO classification other than APL t(15,17), > 60 years, abesence of any other antededent hematologic disease of >8 months, ECOG performance status 0, 1 or 2, life expectancy > 3 months, adequate organ functions to receive intensive chemotherapy

Liens

• euctr
• ictrp